We are live on ! Find out more
NEOS

Neos Therapeutics, Inc
NEOS

Delisted

NEOS was delisted on the 19th of March, 2021.

Back to rankings

37 hedge funds and large institutions have $6.45M invested in Neos Therapeutics, Inc in 2020 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

491% more call options, than puts

Call options by funds: $65K | Put options by funds: $11K

0% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 7

10% less funds holding

Funds holding: 41 → 37 (-4)

26% less capital invested

Capital invested by funds: $8.74M → $6.45M (-$2.29M)

30% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 10

Holders
37
Holders Change
-4
Holders Change %
-9.76%
% of All Funds
0.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
7
Reduced
7
Closed
10
Calls
$65K
Puts
$11K
Net Calls
+$54K
Net Calls Change
+$59K

Top Buyers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
+$357K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$151K
3
Renaissance Technologies
Renaissance Technologies
New York
+$71.5K
4
VF
Virtu Financial
New York
+$10.6K
5
UBS Group
UBS Group
Switzerland
+$7.36K

Top Sellers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
-$2.44M
2
Goldman Sachs
Goldman Sachs
New York
-$1.42M
3
BCM
Bridgeway Capital Management
Texas
-$46.3K
4
TRCT
Tower Research Capital (TRC)
New York
-$13K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$12.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
26
Bank of America
North Carolina
$6K -$935 -1,514 -13%
Cambridge Investment Research Advisors
27
Cambridge Investment Research Advisors
Iowa
$6K +$6.18K +10,000 New
Group One Trading
28
Group One Trading
Illinois
$5K +$5.11K +8,278 +2,531%
Wells Fargo
29
Wells Fargo
California
$2K -$5.34K -8,651 -75%
WEC
30
Winslow Evans & Crocker
Massachusetts
$2K +$1.85K +3,000 New
Citigroup
31
Citigroup
New York
$1K – – –
TFGT
32
TS Financial Group (TSFG)
Illinois
$1K – – –
Morgan Stanley
33
Morgan Stanley
New York
$1K +$124 +200 +19%
BNP Paribas Financial Markets
34
BNP Paribas Financial Markets
France
$6 – – –
NCM
35
Nantahala Capital Management
Connecticut
– -$2.44M -4,610,000 Closed
TRCT
36
Tower Research Capital (TRC)
New York
– -$13K -24,969 Closed
Acadian Asset Management
37
Acadian Asset Management
Massachusetts
– -$8K -15,918 Closed
Millennium Management
38
Millennium Management
New York
– -$8 -15,770 Closed
William Blair & Company
39
William Blair & Company
Illinois
– -$7K -13,400 Closed
Squarepoint
40
Squarepoint
New York
– -$7K -13,220 Closed
Citadel Advisors
41
Citadel Advisors
Florida
– -$6.61K -10,705 Closed
APC
42
Aspire Private Capital
North Carolina
– +$31 +50 New
Simplex Trading
43
Simplex Trading
Illinois
– +$62 +100 New
1
2

NEOS Hedge Fund Activity: Q4 2020 in Review

37 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Neos Therapeutics, Inc (NEOS) for Q4 2020, worth a combined $6.45M — down 26% from $8.74M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of NEOS and 7 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 7 added.

The largest buyer was Stonepine Capital Management, adding an estimated $357K. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $2.44M sold.

  • 37 institutional investors held Neos Therapeutics, Inc (NEOS) as of Q4 2020, down from 41 in Q3 2020.
  • Funds reported $6.45M of Neos Therapeutics, Inc stock for Q4 2020, down 26% quarter-over-quarter.
  • 7 funds opened new Neos Therapeutics, Inc positions in Q4 2020 and 10 closed out, a net change of -3 holders.
  • The largest Neos Therapeutics, Inc buyer in Q4 2020 was Stonepine Capital Management, an estimated $357K added.
  • The largest Neos Therapeutics, Inc seller in Q4 2020 was Nantahala Capital Management, an estimated $2.44M sold.

Based on aggregated 13F filings for Q4 2020.